Sanofi Counts FDA As New Supporter In Lantus Cancer Scare
This article was originally published in The Pink Sheet Daily
Due to "inconsistencies" in European studies, agency is struggling to determine if evidence of cancer risk "truly exists."
You may also be interested in...
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.
In anticipation of the American Diabetes Conference of 2012, analysts take a look at several categories of drugs that will be playing a major role in the future of diabetes care.